TY - JOUR
T1 - Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes
AU - Wang, Shuai
AU - Lin, Xiaohong
AU - Zhu, Chuchen
AU - Dong, Yuqi
AU - Guo, Yiwen
AU - Xie, Zhonghao
AU - He, Xiaoshun
AU - Ju, Weiqiang
AU - Chen, Maogen
N1 - Publisher Copyright:
Copyright © 2024 Wang, Lin, Zhu, Dong, Guo, Xie, He, Ju and Chen.
PY - 2023
Y1 - 2023
N2 - Background: Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of individuals globally. Both serum glucose and albumin were demonstrated to be potential markers for the development of NAFLD. We hypothesized that the risk of NAFLD may be proportional to the glucose-to-albumin ratio (GAR). Methods: Based on information from the National Health and Nutrition Examination Survey (NHANES) 1999–2018, it was determined that GAR was associated with an increased risk of NAFLD and liver fibrosis utilizing weighted multivariable logistic regression. Participants with a fatty liver index (FLI) over 60 were identified with NAFLD, and those with an NAFLD fibrosis score (NFS) >0.676 with evidence of NAFLD were labeled with advanced hepatic fibrosis (AHF). The liver biopsy was utilized to verify the relationship between GAR and FLD in our center cohort. Mendelian randomization analysis investigated the genetic relationship between GAR and NAFLD. Results: Of 15,534 eligible participants, 36.4% of participants were identified as NAFLD without AHF. GAR was positively correlated with the probability of NAFLD following full adjustment for possible variables (OR = 1.53, 95% CI: 1.39–1.67). It was confirmed that patients with NAFLD and AHF had an inferior prognosis. The relationship between GAR and NFS was favorable (R = 0.46, P< 0.0001), and NAFLD patients with a higher GAR tended to develop poor survival. In our center cohort, the association between GAR and NAFLD was verified. Conclusion: Among participants without diabetes, greater GAR was linked to higher risks of NAFLD. In addition, NAFLD patients with higher GAR tended to develop liver fibrosis and adverse outcomes.
AB - Background: Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of individuals globally. Both serum glucose and albumin were demonstrated to be potential markers for the development of NAFLD. We hypothesized that the risk of NAFLD may be proportional to the glucose-to-albumin ratio (GAR). Methods: Based on information from the National Health and Nutrition Examination Survey (NHANES) 1999–2018, it was determined that GAR was associated with an increased risk of NAFLD and liver fibrosis utilizing weighted multivariable logistic regression. Participants with a fatty liver index (FLI) over 60 were identified with NAFLD, and those with an NAFLD fibrosis score (NFS) >0.676 with evidence of NAFLD were labeled with advanced hepatic fibrosis (AHF). The liver biopsy was utilized to verify the relationship between GAR and FLD in our center cohort. Mendelian randomization analysis investigated the genetic relationship between GAR and NAFLD. Results: Of 15,534 eligible participants, 36.4% of participants were identified as NAFLD without AHF. GAR was positively correlated with the probability of NAFLD following full adjustment for possible variables (OR = 1.53, 95% CI: 1.39–1.67). It was confirmed that patients with NAFLD and AHF had an inferior prognosis. The relationship between GAR and NFS was favorable (R = 0.46, P< 0.0001), and NAFLD patients with a higher GAR tended to develop poor survival. In our center cohort, the association between GAR and NAFLD was verified. Conclusion: Among participants without diabetes, greater GAR was linked to higher risks of NAFLD. In addition, NAFLD patients with higher GAR tended to develop liver fibrosis and adverse outcomes.
KW - advanced hepatic fibrosis
KW - diabetes
KW - donor liver
KW - glucose-albumin ratio
KW - nonalcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85182699491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182699491&partnerID=8YFLogxK
U2 - 10.3389/fendo.2023.1287916
DO - 10.3389/fendo.2023.1287916
M3 - Article
AN - SCOPUS:85182699491
SN - 1664-2392
VL - 14
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1287916
ER -